Pharmacogenomics of CRC treatments: putting bricks on the path to personalized medicine

BMC Genomics

Oral Presentation

Mahmood Rasool¹  Clara Ruiz-Ponte²  Alejandro Brea-Fernández²  Francisco Barros²  Emilia Balboa³  Angel Carracedo⁴  Ceres Fernández-Rozadilla⁵  Sergi Castellvi-Bel⁶  Antoni Castells⁶ 

[1] Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Post Box: 80216, 21589, Jeddah, KSA;Galician Foundation of Genomic Medicine, IDIS, SERGAS, 15706 Santiago de Compostela, Spain;Genomic Medicine Group-CIBERER, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain;Genomic Medicine Group-CIBERER, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain;Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Post Box: 80216, 21589, Jeddah, KSA;Galician Foundation of Genomic Medicine, IDIS, SERGAS, 15706 Santiago de Compostela, Spain;Genomic Medicine Group-CIBERER, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain;Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, OX3 7BN, Oxford, UK;Servicio de Gastroenterología, Hospital Clínic, IDIBAPS, Universitat de Barcelona, CIBERehd, Barcelona, Spain;

关键词: Oxaliplatin;    Drug Response;    Personalized Medicine;    Narrow Therapeutic Index;    Genomic Medicine;   

DOI  :  10.1186/1471-2164-15-S2-O5

来源: Springer

【 授权许可】

Unknown   
© Fernández-Rozadilla et al; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.